Clinical Trial Update: JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial updating the use of JTX-2011 alone and in combination with anti-PD-1 or anti-CTLA-4 in advanced or refractory solid tumors has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• JTX-2011 (unknown)

Snippet

Sponsor: Jounce Therapeutics, Inc. | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-09